pharmaceut rate reiter unit state go sg websit
miss wood tree
uncertainti shape humira eros curv biosimilar competit
start us perceiv increas risk dilut
left share trade histor low price-to-earnings manag
appar share concern hoard cash buy
troubl return industry-lead sum sharehold
share manag view long-rang lrp target
risk-adjust non-humira revenu transform
sustain busi later year expect launch two
import lrp pipelin drug segment alreadi market
leader trigger rerat
forecast upsid surpris ep forecast ahead
consensu expect sale margin growth drive materi upsid
top line project humira blood cancer base busi pipelin
surpris posit addit input manag lrp estim model
impli upsid potenti consensu ep furthermor none
factor phase peak sale potenti calcul alon
valu stock target price still base straight averag
ev/ebita multipl dcf valuat plug lrp straight
valuat model would impli valuat els equal unchang
tp impli price-to-earnings discount peer group appropri balanc
abbv above-averag short-term growth prospect long-term challeng
input dividend per share project tsr remain
upsid tp
nc chang
could wrong identifi three downsid risk group ebita
forecast abbv two highest-profil pipelin product risankizumab
upadacitinib fail abbv phase trial imbruvica blood cancer fail
drug lose exist sale competit
biosimilar impact humira prove neg us outsid us
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
creat via spin-out abbott lab pharma busi humira
treat autoimmun diseas rheumatoid arthriti account abbv
group revenu follow unsuccess attempt acquir shire bought
blood cancer specialist pharmacycl bid diversifi away humira
consensu expect face biosimilar gener competit
intern market addit inflamm cancer abbv key area
therapeut focu virolog women health neurosci result stage
publish long-rang lrp includ risk-adjust non-humira revenu
forecast
product relev invest debat
via knoll acquisit
via pharmacycl acquisit
jv roch book sale
in-licens boehring ingelheim
in-licens neurocrin bioscienc
invest debat
reason
reason
lack therapeut diversif
gener dividend buyback free cash flow return
 track record spent acquir us right imbruvica
next five year estim
 spent secur ex-u right
transform stori pipelin surpris upsid off-set
patent cliff humira imbruvica
under-perform
year date far worst perform larg cap pharma stock coverag
univers believ two reason
 risk remind buy announc januari
agre acquir us biotech celgen rate cash stock
news led investor specul whether might launch counter bid bristol
myer squibb tri improv fundament diversifi away humira
would see strateg rational deal bristol myer squibb
immunotherapi busi target solid cancer would materi complement
abbvi blood cancer busi howev view deal would like
dilut short-term earn substanti amount new equiti would
rais calcul current net debt/ebitda
worsen gener headwind humira began face biosimilar competit outsid
us result call indic expect sale product
erod mid-to-high percentag rang region howev
result call manag suggest drug like declin
outsid us year led investor extrapol biosimilar competit
drug commenc insid us like wors expect
sale humira us roughli doubl outsid us
still bullish stock
matter best practic whenev convict call stop work systemat
thoroughli review bottom-up assumpt done reiter
buy rate three key reason
non-gaap ep sg estim comparison consensu
see materi upsid risk consensu ep estim see tabl expect
sale margin surpris posit chart top line project base
busi humira blood cancer pipelin surpris posit
ep sourc varianc sge vs consensu
group sale sourc varianc sge vs consensu
note blood cancer imbruvica venclexta pipelin risankizumab upadacitinib
note blood cancer imbruvica venclexta pipelin risankizumab upadacitinib
recap humira largest-sel drug world market leader
anti-tnf class drug segment treat inflammatori diseas caus overact
immun system rheumatoid arthriti sale humira us far exceed outsid
us howev provid specif guidanc shape us eros
curv intern forecast humira post entri biosimilar like
earli still think eros curv remicad key competitor us better
compar humira outsid us payer structur market
differ exampl european countri oper winner take tender
biosimilar wherea us moreov us much larger privat insur
market europ
background biosimilar version js remicad launch us sale
erod mid-teen annual basi sinc anoth humira import
competitor enbrel unlik face biosimilar competit us earliest
litig still delay launch sever biosimilar approv fda sinc
think humira estim could ahead consensu forecast benign
eros drug us market see left-hand chart import
recal diseas drug treat chronic debilit effect
treat result signific cost healthcar system due increas absente
work therefor expect us patient well control abbvi brand
switch onto biosimilar save money howev acknowledg
biosimilar captur volum new patient view born
channel check compani manufactur equip biosimilar
manufactur need produc product sell less compani
intend launch biosimilar humira sell biosimilar version anti-canc drug
roch rituxan
humira sourc sg forecast bn
venclexta sourc sg forecast
view continu execut well imbruvica howev blood cancer
franchis estim higher consensu due venclexta suspect could
market discount diseas compani either present
run phase trial chart right
in-licens boehring ingelheim
two import drug abbv late-stag pipelin immuno-inflamm asset
risankizumab upadacitinib see tabl recap result
octob present long-rang lrp target risk-adjust non-
humira revenu excess forecast strategi present
manag also target nomin probability-weight sale risankizumab
upadacitinib respect sinc compani publish
solid phase data product see addendum henc healthcar confer
januari compani said expect product collect contribut
risk-adjust sale
calcul consensu drug combin latest avail year
less new risk-adjust forecast think gap larg
market place much emphasi number new entrant class see
addendum enough sheer size market chart risankizumab
forecast higher consensu concur market far
like shape rise tide dynam rather one size fit
manag deliv lrp calcul could potenti upsid
consensu ep would expect market confid lrp increas
execut well launch risankizumab upadacitinib
remind spun abbott lab recent share price
under-perform mean forward price-to-earnings record low see chart left
outlier vs peer see chart right suspect investor
believ compani abl grow humira lose exclus
us earli
deliv lrp estim year pre compani
deliv below-averag growth year biosimilar competit
humira commenc us see bull line chart acknowledg
forecast neg ep growth due imbruvica patent expiri
howev growth rate includ contribut phase pipelin
view contain interest asset see tabl also believ
compani alreadi earmark ampl spend purpos
bolster early-stag pipelin addit forecast compani back net
cash full three year imbruvica begin face gener competit
result posit trial could start
meaning innov sinc avastin launch
exist gold standard jakafi expect peak face gener
competit result success
like tri prove superior jakafi treatment-na patient celg
us target fedratininb launch peak sale
target patient over-express c-met mutat account
non-small-cel lung cancer lung cancer patient
diseas
alzheim diseas often fail come fruition peak sale
heavili risk adjust unmet need progress supranuclear palsi
high
could also develop crohn diseas lupu sjogren syndrom
combin btk inhibitor upadacitinib jak inhibitor
administ intraven infus phase trial relaps
har tripl combo line recent breakthrough vertex
symdeko sale expect peak
note alway base target price unweight averag near-term multipl
dcf automat take account stock short- long-term growth prospect
appli perpetu growth rate dcf mean exit
valu account total ev
target price still base straight averag ev/ebita multipl
dcf valuat note plug lrp straight valuat model impli
valuat els equal tp impli price-to-earnings discount
peer group appropri balanc abbv above-averag short-term growth prospect
long-term challeng
shown chart left forecast cumul gener
post-tax free cash half return sharehold via
dividend buyback shown chart right suggest
attract incom stori global pharma coverag univers
could wrong
us sale humira onward erod rate impli guidanc
product outsid us calcul would downsid group
ebita forecast acknowledg humira highli profit howev view
also strong probabl potenti downsid could mitig phase
pipelin discuss stage group guid non-humira risk-
adjust revenu forecast risk-adjust non-humira sale
explain risankizumab upadacitinib abbv two import pipelin
product chart left either one drug fail reach market
would downsid current ebita estim project fail
would downsid estim
imbruvica sourc sale
note pipelin venclexta rova-t orilissa depatuxizumab upadacitinib
waldenstrom macroglobulinemia global sale book
show right-hand chart chronic lymphocyt leukaemia cll
imbruvica alreadi approv set largest driver drug growth medium
term treatment-na tn cll forecast three time higher relaps
remit r/r cll popul former much larger relev
astrazeneca azn run phase head-to-head trial r/r cll imbruvica versu
btk inhibitor acalabrutinib due read addit azn confid
acalabrutinib take share imbruvica benign side-effect profil even
though indic chronic use channel check suggest patient
discontinu imbruvica side effect atrial fibril heart flutter pain
azn trial success acalabrutinib captur imbruvica r/r cll sale
would mid-single-digit percentag downsid risk ebit estim
year moreov abbv phase trial imbruvica potenti new indic fail
would low single-digit percentag downsid ebita forecast
addendum scenario analysi
chart model impact central scenario posit
neg take relev product current portfolio late-
stage pipelin help us calibr magnitud risk compani face
come year use ebita analysi given long product cycl
pharmaceut industri model signal upsid risk ebita
estim downsid vs
sale varianc sourc upsid downsid
ebit varianc sourc upsid downsid
driver drag sale
summari product sale
 revenuedeclin revenu sale
product sold
equival
total liabil equiti
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
purchas treasuri stock
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
upadacitinib janu kinas jak inhibitor jak inflammatori mediat
play import role sever autoimmun diseas drug complet phase trial
rheumatoid arthriti ra also phase crohn diseas inflammatori diseas
bowel ulcer coliti psoriat arthriti atop dermat type skin inflamm
differ psoriasi phase trial giant cell arter axial spa expect start
anti-tnf product profil sale
sc everi week
sc
shown tabl anti-tnf drug approv use wide treat ra
howev disadvantag product administ inject either
subcutan vein pain and/or time consum
upadacitinib baricitinib investig compound develop respect data present head-to-head studi data deriv
select-next select-beyond studi ra-build ra-beacon studi addit phase data baricitinib shown addit phase
studi upadacitinib on-going
jak inhibitor conveni anti-tnf deliv bodi tablet
form howev perform first-in-class jak inhibitor pfizer xeljanz
underwhelm sale fourth full year market argu
us reimburs hurdl sheer size rebat tnf
manufactur give insur compani rather xeljanz side effect profil
caus anaemia tired due lower red blood cell count inhibit
receptor anti-inflammatori effect caus block increas
risk cancer risk cite black box warn drug prescrib inform
approv
ph
ph
ph award btd ph start
ph start
ph
ph
hope differenti upadacitinib xeljanz term safeti efficaci
claim upadacitinib select theori mean
less like caus anaemia cancer risk associ upadacitinib also lower
xeljanz given claim select phase data
date indic upadacitinib highli competit profil chart
upadacitinib sourc us revenu
note ra rheumatoid arthriti ad atop dermat psa/a psoriat arthriti
note ra rheumatoid arthriti ad atop dermat psa/a psoriat arthriti
in-licens global right risankizumab boehring ingelheim
psoriasi common chronic relapsing/remit auto-immun diseas characteris skin
lesion red plaqu usual itch psoriasi develop immun system mistak
normal skin cell pathogen send faulti signal caus overproduct
new skin cell sever diseas measur psoriasi area sever
pasi defin percentag bodi surfac cover plaqu less
coverag two-third affect popul mild form diseas
sever form psoriasi affect less suffer
pasi week
vs placebo
titrat due gi side
effect
day
pasi week
vs placebo
week
month
pasi week
vs placebo
pasi week
market moder
phototherapi
system therapi
stelara
pasi week
vs placebo
pasi non-
anti-tnf respond
phase pasi
sc everi
week two
load dose first
start dose
approv februari
us
black box warn
approv us
review europ
regulatori file
sc everi pasi vs
diseas clinic
coliti uc
last one
bimekizumab psoriasi
phase ii pasi
pasi
phase result pso
due
pasi vs
humira week
psoriasi market domin topic agent phototherapi non-sever form
mainli corticosteroid mild-to-sever form treat system agent regard
latter largest class inject drug anti-tnf show good efficaci
patient time stelara launch becam
drug last year virtu innov mechan action efficaci shown
tabl risankizumab belong class although sever potenti
new entrant market hope differenti product base
efficaci see chart conveni unlik competitor dose
risankizumab complet phase trial psoriasi expect fda
approv indic drug also phase trial crohn diseas
escap occur treatment longer effect
risankizumab phase immvent studi moderate-to-sever psoriasi patient
above-consensu forecast conserv
shown tabl risankizumab estim higher consensu
suspect market overestim potenti impact new entrant
underestim impact product cycl and/or underestim size market
tnf-inadequ respond estim us psoriasi patient
treat biolog outsid us estim level intern
busi plan project nomin sale risankizumab year
estim risk-adjust sale probabl
sourc us revenu
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
flow invest activ
flow financ activ
net chang cash result cf
intang
america corp
depreci amortis
chang work capit
flow oper activ
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
straight averag sotp base averag ev/ebita multipl dcf wacc termin growth
identifi three sourc downsid group ebita forecast abbv two highest profil pipelin product
risankizumab upadacitinib fail abbv phase trial imbruvica blood cancer fail drug lose
exist sale competit biosimilar impact humira neg us outsid us
sg equiti research rate month period
equiti rate dispers relationship
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
